Panaxia Pharmaceuticals

Panaxia Pharmaceuticals is a leading Israeli pharmaceutical company specializing in the development, manufacturing, and marketing of medical cannabis products produced to EU-GMP standards. As part of the Segal Pharma Group, the company leverages over four decades of pharmaceutical expertise to create advanced delivery methods, including sublingual tablets, metered-dose inhalers, and suppositories. Panaxia focuses on providing consistent, evidence-based cannabinoid therapies for indications such as chronic pain, PTSD, and oncology-related symptoms. The company maintains a significant international presence through strategic partnerships, particularly in Europe, and is publicly traded on the Tel Aviv Stock Exchange. Their business model emphasizes high-quality pharmaceutical-grade manufacturing and clinical validation of cannabis-based medicines.